Cargando…
The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts
Sclerostin is a bone formation inhibitor produced by osteocytes. Although sclerostin is mainly expressed in osteocytes, it was also reported in periodontal ligament (PDL) fibroblasts, which are cells that play a role in both osteogenesis and osteoclastogenesis. Here, we assess the role of sclerostin...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145870/ https://www.ncbi.nlm.nih.gov/pubmed/37108735 http://dx.doi.org/10.3390/ijms24087574 |
_version_ | 1785034441971728384 |
---|---|
author | Pigeaud, Karina E. Rietveld, Melanie L. Witvliet, Aster F. Hogervorst, Jolanda M. A. Zhang, Chen Forouzanfar, Tim Bravenboer, Nathalie Schoenmaker, Ton de Vries, Teun J. |
author_facet | Pigeaud, Karina E. Rietveld, Melanie L. Witvliet, Aster F. Hogervorst, Jolanda M. A. Zhang, Chen Forouzanfar, Tim Bravenboer, Nathalie Schoenmaker, Ton de Vries, Teun J. |
author_sort | Pigeaud, Karina E. |
collection | PubMed |
description | Sclerostin is a bone formation inhibitor produced by osteocytes. Although sclerostin is mainly expressed in osteocytes, it was also reported in periodontal ligament (PDL) fibroblasts, which are cells that play a role in both osteogenesis and osteoclastogenesis. Here, we assess the role of sclerostin and its clinically used inhibitor, romosozumab, in both processes. For osteogenesis assays, human PDL fibroblasts were cultured under control or mineralizing conditions with increasing concentrations of sclerostin or romosozumab. For analyzing osteogenic capacity and alkaline phosphatase (ALP) activity, alizarin red staining for mineral deposition and qPCR of osteogenic markers were performed. Osteoclast formation was investigated in the presence of sclerostin or romosozumab and, in PDLs, in the presence of fibroblasts co-cultured with peripheral blood mononuclear cells (PBMCs). PDL-PBMC co-cultures stimulated with sclerostin did not affect osteoclast formation. In contrast, the addition of romosozumab slightly reduced the osteoclast formation in PDL-PBMC co-cultures at high concentrations. Neither sclerostin nor romosozumab affected the osteogenic capacity of PDL fibroblasts. qPCR analysis showed that the mineralization medium upregulated the relative expression of osteogenic markers, but this expression was barely affected when romosozumab was added to the cultures. In order to account for the limited effects of sclerostin or romosozumab, we finally compared the expression of SOST and its receptors LRP-4, -5, and -6 to the expression in osteocyte rich-bone. The expression of SOST, LRP-4, and LRP-5 was higher in osteocytes compared to in PDL cells. The limited interaction of sclerostin or romosozumab with PDL fibroblasts may relate to the primary biological function of the periodontal ligament: to primarily resist bone formation and bone degradation to the benefit of an intact ligament that is indented by every chew movement. |
format | Online Article Text |
id | pubmed-10145870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101458702023-04-29 The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts Pigeaud, Karina E. Rietveld, Melanie L. Witvliet, Aster F. Hogervorst, Jolanda M. A. Zhang, Chen Forouzanfar, Tim Bravenboer, Nathalie Schoenmaker, Ton de Vries, Teun J. Int J Mol Sci Article Sclerostin is a bone formation inhibitor produced by osteocytes. Although sclerostin is mainly expressed in osteocytes, it was also reported in periodontal ligament (PDL) fibroblasts, which are cells that play a role in both osteogenesis and osteoclastogenesis. Here, we assess the role of sclerostin and its clinically used inhibitor, romosozumab, in both processes. For osteogenesis assays, human PDL fibroblasts were cultured under control or mineralizing conditions with increasing concentrations of sclerostin or romosozumab. For analyzing osteogenic capacity and alkaline phosphatase (ALP) activity, alizarin red staining for mineral deposition and qPCR of osteogenic markers were performed. Osteoclast formation was investigated in the presence of sclerostin or romosozumab and, in PDLs, in the presence of fibroblasts co-cultured with peripheral blood mononuclear cells (PBMCs). PDL-PBMC co-cultures stimulated with sclerostin did not affect osteoclast formation. In contrast, the addition of romosozumab slightly reduced the osteoclast formation in PDL-PBMC co-cultures at high concentrations. Neither sclerostin nor romosozumab affected the osteogenic capacity of PDL fibroblasts. qPCR analysis showed that the mineralization medium upregulated the relative expression of osteogenic markers, but this expression was barely affected when romosozumab was added to the cultures. In order to account for the limited effects of sclerostin or romosozumab, we finally compared the expression of SOST and its receptors LRP-4, -5, and -6 to the expression in osteocyte rich-bone. The expression of SOST, LRP-4, and LRP-5 was higher in osteocytes compared to in PDL cells. The limited interaction of sclerostin or romosozumab with PDL fibroblasts may relate to the primary biological function of the periodontal ligament: to primarily resist bone formation and bone degradation to the benefit of an intact ligament that is indented by every chew movement. MDPI 2023-04-20 /pmc/articles/PMC10145870/ /pubmed/37108735 http://dx.doi.org/10.3390/ijms24087574 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pigeaud, Karina E. Rietveld, Melanie L. Witvliet, Aster F. Hogervorst, Jolanda M. A. Zhang, Chen Forouzanfar, Tim Bravenboer, Nathalie Schoenmaker, Ton de Vries, Teun J. The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts |
title | The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts |
title_full | The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts |
title_fullStr | The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts |
title_full_unstemmed | The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts |
title_short | The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts |
title_sort | effect of sclerostin and monoclonal sclerostin antibody romosozumab on osteogenesis and osteoclastogenesis mediated by periodontal ligament fibroblasts |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145870/ https://www.ncbi.nlm.nih.gov/pubmed/37108735 http://dx.doi.org/10.3390/ijms24087574 |
work_keys_str_mv | AT pigeaudkarinae theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT rietveldmelaniel theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT witvlietasterf theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT hogervorstjolandama theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT zhangchen theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT forouzanfartim theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT bravenboernathalie theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT schoenmakerton theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT devriesteunj theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT pigeaudkarinae effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT rietveldmelaniel effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT witvlietasterf effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT hogervorstjolandama effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT zhangchen effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT forouzanfartim effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT bravenboernathalie effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT schoenmakerton effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts AT devriesteunj effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts |